Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00280-011-1801-yPMID 22205202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• UHRF1 confers radioresistance to human breast cancer cells

  2011cited by this paper
• UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis.

  2011cited by this paper
• UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs

  2010cited by this paper
• UHRF1 is a novel diagnostic marker of lung cancer

  2010cited by this paper
• UHRF1 is a genome caretaker that facilitates the DNA damage response to γ-irradiation

  2010cited by this paper
• Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis.

  2009cited by this paper
• UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells

  2008cited by this paper
• UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells

  2007cited by this paper
• Np95 is implicated in pericentromeric heterochromatin replication and in major satellite silencing.

  2007cited by this paper
• The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA

  2007cited by this paper
• Tissue-specific and cell type–specific RNA interference in vivo

  2006cited by this paper
• Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis.

  2005cited by this paper
• Survivin as a target for new anticancer interventions

  2005cited by this paper
• Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.

  2005cited by this paper
• Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth.

  2005cited by this paper
• Molecular Cloning of Survivin Gene Promoter and Detecting Its Specific Activity in HeLa Cell

  2005cited by this paper
• The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle

  2005cited by this paper
• Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?

  2005cited by this paper
• ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain

  2004cited by this paper
• Cancer-specific activation of the survivin promoter and its potential use in gene therapy

  2004cited by this paper
• Role of survivin and its splice variants in tumorigenesis

  2004cited by this paper
• Overexpression of NP95 mRNA by tumor promoters in the promotion phase of a two-stage BALB/3T3 cell transformation assay.

  2003cited by this paper
• A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA

  2003cited by this paper
• ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells

  2003cited by this paper
• A DNA vector-based RNAi technology to suppress gene expression in mammalian cells

  2002cited by this paper
• Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry

  2002cited by this paper
• Targeted Disruption of Np95 Gene Renders Murine Embryonic Stem Cells Hypersensitive to DNA Damaging Agents and DNA Replication Blocks*

  2002cited by this paper
• The platinum agents: a role in breast cancer treatment?

  2001cited by this paper
• ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.

  2000cited by this paper
• Cisplatin as first-line therapy for metastatic breast cancer.

  1988cited by this paper

• Targeted RASSF1A expression inhibits proliferation of HER2‑positive breast cancer cells in vitro.

  2023cites this paper
• Plumbagin downregulates UHRF1, p-Akt, MMP-2 and suppresses survival, growth and migration of cervical cancer CaSki cells.

  2022cites this paper
• Inhibition of Protein Disulfide Isomerase (PDIA1) Leads to Proteasome-Mediated Degradation of Ubiquitin-like PHD and RING Finger Domain-Containing Protein 1 (UHRF1) and Increased Sensitivity of Glioblastoma Cells to Topoisomerase II Inhibitors.

  2022cites this paper
• CMAR_A_311192 4841..4852

  2021cites this paper
• Silencing UHRF1 Enhances Radiosensitivity of Esophageal Squamous Cell Carcinoma by Inhibiting the PI3K/Akt/mTOR Signaling Pathway

  2021cites this paper
• UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer

  2020cites this paper
• UHRF1 drives the poor prognosis associated with RB loss in osteosarcoma

  2020cites this paper
• UHRF1 is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

  2020cites this paper
• UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells

  2019cites this paper
• epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies

  2019cites this paper
• Epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies

  2019cites this paper
• Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms

  2019cites this paper
• Silencing UHRF1 Inhibits Cell Proliferation and Promotes Cell Apoptosis in Retinoblastoma Via the PI3K/Akt Signalling Pathway

  2019cites this paper
• Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation

  2018cites this paper
• Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.

  2017cites this paper
• The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer

  2017cites this paper
• UHRF1 promotes breast cancer progression by suppressing KLF17 expression by hypermethylating its promoter.

  2017cites this paper
• Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma

  2017cites this paper
• Survivin, a Promising Gene for Targeted Cancer Treatment.

  2016cites this paper
• Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p

  2016cites this paper
• UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy

  2016cites this paper
• Knockdown of UHRF 1 by Lentivirus-mediated shRNA Inhibits Ovarian Cancer Cell Growth

  2015cites this paper
• Supramolecular Assembly Models of siRNA Delivery Systems

  2015cites this paper
• Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma.

  2015cites this paper
• Elevated expression of UHRF 1 predicts unfavorable prognosis for patients with hepatocellular carcinoma

  2015cites this paper
• Knockdown of UHRF1 by lentivirus-mediated shRNA inhibits ovarian cancer cell growth.

  2015cites this paper
• Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.

  2015cites this paper
• Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis.

  2013cites this paper
• Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes.

  2013cites this paper